Myrrh

Botanical name: Commiphora molmol

Myrrh.jpg

© Steven Foster

Parts used and where grown

Myrrh grows as a shrub in desert regions, particularly in northeastern Africa and the Middle East. The resin obtained from the stems is used in medicinal preparations.

Myrrh has been used in connection with the following conditions (refer to the individual health concern for complete information):

Rating Health Concerns
2Stars

Gingivitis (periodontal disease) (as mouthwash, in combination with sage, peppermint oil, menthol, chamomile tincture, expressed juice from echinacea, clove oil, and caraway oil)

Parasites (schistosomiasis)

1Star

Canker sores

Cervical smear (abnormal)

Cold sores

Common cold/sore throat

Halitosis (rinse)

Infection

Ulcerative colitis

3Stars Reliable and relatively consistent scientific data showing a substantial health benefit.
2Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
1Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit.

Historical or traditional use (may or may not be supported by scientific studies)

In ancient times, the red-brown resin of myrrh was used to preserve mummies. It was also used as a remedy for numerous infections, including leprosy and syphilis. Myrrh was also recommended by herbalists for relief from bad breath and for dental conditions.1 In Traditional Chinese Medicine, it has been used to treat bleeding disorders and wounds.

Active constituents

The three main constituents of myrrh are the resin, the gum, and the volatile oil. All are thought to be important in myrrh’s activity as an herbal medicine. The resin has reportedly been shown to kill various microbes and to stimulate macrophages (a type of white blood cell) in test tube studies.2 Myrrh also has astringent properties and has a soothing effect on inflamed tissues in the mouth and throat. Studies continue on the potential anticancer and pain-relieving actions of myrrh resin.3 4 Human clinical trials are lacking to confirm most uses of myrrh.

In a preliminary trial, patients with schistosomiasis (a parasitic infection) were treated with a combination of resin and volatile oil of myrrh, in the amount of 10 mg per 2.2 pounds of body weight per day for three days. The cure rate was 91.7% and, of those who did not respond, 76.5% were cured by a second six-day course of treatment, increasing the overall cure rate to 98.1%.5

How much is usually taken?

The German Commission E monograph recommends that persons either dab the undiluted tincture in the mouth or gargle with 5–10 drops of tincture in a glass of water three times daily.6 In addition, tincture of myrrh, 1–2 ml three times per day, can be taken. The tincture can also be applied topically for canker sores. Due to the gummy nature of the product, a tea cannot be made from myrrh. Capsules, containing up to 1 gram of resin taken three times per day, can be used as well.

Are there any side effects or interactions?

No adverse effects from myrrh usage have been reported.

At the time of writing, there were no well-known drug interactions with myrrh.

References

1. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 2d ed. New York: John Wiley & Sons, 1996, 382–3.

2. Mills SY. Out of the Earth: The Essential Book of Herbal Medicine. Middlesex, UK: Viking Arkana, 1991, 500–2.

3. Al-Harbi MM, Qureshi S, Raza M, et al. Anticarcinogenic effect of Commiphora molmol on solid tumors induced by Ehrlich carcinoma cells in mice. Chemotherapy 1994;40:337–47.

4. Dolara P, Luceri C, Ghelardini C, et al. Analgesic effects of myrrh. Nature 1996;376:29.

5. Sheir Z, Nasr AA, Massoud A, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 2001;65:700–4.

6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 173–4.